Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
References (Scientific Literature) PMCID: PMC2249747 (1) PMCID: PMC8078644 PMCID: PMC7462336 PMID: 23631796 PMID: 11056412 PMID: 10575337
If bubbles are present, gently tap the syringe and push them out before refilling
The safety profile of retatrutide is similar to other incretin-based therapies, with the most commonly reported adverse events being transient and mostly mild to moderate gastrointestinal symptoms, with the 4 mg starting dose group having a higher incidence than the 2 mg starting dose group
Back AAAS EurekAlert (18 Dec 2023) 'Toronto study identifies new concepts for GLP-1 action in the brain, the 2023 Science magazine breakthrough of the year'
US$ 28.78
US$ 21.96
US$ 27.64
US$ 21.10
US$ 25.41
US$ 29.02
US$ 20.87
